Home  »  Finance   »  Do Analysts Recommend You Should Buy NewAge, Inc. ...

Do Analysts Recommend You Should Buy NewAge, Inc. (NBEV) Stock?

On Monday, shares of NewAge, Inc. (NASDAQ:NBEV) marked $2.54 per share versus a previous $2.84 closing price. With having a -10.56% loss, an insight into the fundamental values of NewAge, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. NBEV showed a rise of 39.56% within its YTD performance, with highs and lows between $0.98 – $3.22 during the period of 52 weeks, compared to the simple moving average of 42.35% in the period of the last 200 days.

Alliance Global Partners equity researchers changed the status of NewAge, Inc. (NASDAQ: NBEV) shares to a “Buy” rating in the report published on November 15th, 2019. Other analysts, including Northland Capital, also published their reports on NBEV shares. Northland Capital repeated the rating from the previous report, marking NBEV under “Market Perform” rating, in the report published on July 22nd, 2019. Additionally, NBEV shares got another “Buy” rating from Alliance Global Partners, setting a target price of $8 on the company’s shares, according to the report published in March 26th, 2019. On the other hand, Northland Capital Initiated the “Outperform” rating for NBEV shares, as published in the report on September 4th, 2018. Maxim Group seems to be going bullish on the price of NBEV shares, based on the price prediction for NBEV, indicating that the shares will jump from $7.50 to $6, giving the shares “Buy” rating based on their report from November 17th, 2017. Another “Buy” rating came from ROTH Capital, providing a prediction for $6 price target according to the report published in July 27th, 2017.

[bold-text]NewAge, Inc. (NBEV) Analysis[/bold-text]

The present dividend yield for NBEV owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. In addition, the growth of sales from quarter to quarter is recording -5.60%, hinting the company’s progress in the upcoming progress.

In order to gain a clear insight on the performance of NewAge, Inc. (NBEV) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance. In this case, you want to make sure that the return on the present equity of -91.20% is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at 1.00 so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.

Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while NBEV is currently recording an average of 2.03M in volumes. The volatility of the stock on monthly basis is set at 8.33%, while the weekly volatility levels are marked at 10.88%with 4.53% of gain in the last seven days.

[bold-text]What to Look for When Analyzing NewAge, Inc. Shares?[/bold-text]

NewAge, Inc. (NBEV) is based in the USA and it represents one of the well-known company operating with Consumer Defensive sector. If you wish to compare NBEV shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of for NewAge, Inc., while the value 11.55 can represent an indicator in the future growth of the company in terms of investor’s expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value -1.21 is supported by the yearly EPS growth of -345.10%.

Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 1.00%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives’ share, the institutional ownership counts 23.00% of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.

[bold-text]Are Institutional Investors Increasing Stakes in NBEV Shares?[/bold-text]

It appears that more than several institutional investors and hedge funds decided to increase stakes in NBEV in the recent period. That is how BlackRock Fund Advisors now has an increase position in NBEV by 11.43% in the first quarter, owning 5.45 million shares of NBEV stocks, with the value of $9.42 million after the purchase of an additional 558,537 shares during the last quarter. In the meanwhile, The Vanguard Group, Inc. also increased their stake in NBEV shares changed 34.98% in the first quarter, which means that the company now owns 5.25 million shares of company, all valued at $9.08 million after the acquisition of additional 1,360,647 shares during the last quarter.

Geode Capital Management LLC acquired a new position in NewAge, Inc. during the first quarter, with the value of $2.08 million, and Northern Trust Investments, Inc. increased their stake in the company’s shares by 7.34% in the first quarter, now owning 69,288 shares valued at $1.75 million after the acquisition of the additional 1.01 million shares during the last quarter. In the end, Requisite Capital Management LLC increased their position by — during the first quarter, now owning 500000 NBEV shares, now holding the value of $865000 in NBEV with the purchase of the additional 0 shares during the period of the last quarter. At the present, 23.00% of NBEV shares are in the ownership of institutional investors.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

3 Top Biotech Stocks to Watch

Companies in the biotechnology industry work on the development of drugs and diagnostic technologies to treat medical conditions and diseases. Most Biotech products must undergo